If you missed the live webinar, don’t worry — the full recording is available below.   https://www.youtube.com/watch?v=qM9b0n2_L0c&t=1226s   In this session, we introduce SILCS v2026, including several new capabilities and workflow enhancements designed to improve interpretability, efficiency, and decision‑making in computational drug discovery. This update may be particularly relevant for those working on lead [...]

April 21, 2026, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, is excited to announce the hiring of Ashlin Poruthoor, Ph.D. as Applications Scientist. Ashlin has been a post-doctoral fellow with Prof. Alexander MacKerell at the University of Maryland Baltimore investigating novel fingerprints for ML-AI [...]

Targeting transcription factors that act as master regulators of cancer progression has long been an important goal in oncology drug discovery. Among the most prominent of these are hypoxia-inducible factors 1 and 2 (HIF‑1 and HIF‑2), which orchestrate broad transcriptional programs that drive tumor growth, angiogenesis, metastasis, and immune evasion. Despite their importance, effectively targeting [...]

FOR IMMEDIATE RELEASE Baltimore, MD — October 23, 2025 — SilcsBio, a leader in physics-based computational drug design, is proud to announce the launch of the SilcsBio Software - Covalent Suite, an innovative addition to its expanding portfolio of drug discovery solutions. Designed to accelerate the discovery of targeted covalent inhibitors (TCIs), the Covalent Suite empowers [...]

We recently hosted our SILCS v2025 Release Webinar, showcasing the latest advancements in our cutting-edge molecular modeling platform. If you missed it, now’s your chance to catch up! SILCS v2025 brings major enhancements to accuracy, usability, and flexibility, enabling researchers to accelerate drug discovery like never before. From enhanced SILCS-MC docking to machine learning-powered hotspot [...]